课题基金 / 基金详情

SYNTHESIS OF ADRIAMYCIN SUGARS AND THIENAMYCIN

SYNTHESIS OF ADRIAMYCIN SUGARS AND THIENAMYCIN
阿霉素糖和硫霉素的合成
批准号:
3171839
负责人:
M MARK MIDLAND
金额:
$2.88万
依托单位国家:
美国
项目类别:
财政年份:
1983
资助国家:
美国
项目状态:
已结题
起止时间:
1983-02-01 至 1986-01-31

项目摘要

项目成果

M MARK MIDLAND的其他基金

相似基金

相关文献

中文摘要
翻译
阿霉素是蒽环类抗生素家族的一员, 被发现对各种癌症都非常有效。 硫霉素是一种β-内酰胺类抗生素, 它对革兰氏阳性和 革兰氏阴性菌 这些分子中的手性对 在生物活动中的作用。 因此,光学合成 这些化合物的活性形式是重要的。 我们最近开发了 两种制备光学活性分子的新方法:不对称 通过三烷基硼烷的还原,以及在 有机硼酸盐重排的迁移终点。 不对称 炔丙基酮的还原制得基本上光学纯的炔丙基 酒精容易获得,乙炔手柄使酒精 有吸引力的中间体,用于进一步加工。 研究 有机硼烷重排使得光学活性的烯丙基硼烷容易地 第一次接触到。 这些有机硼烷与酮的加成 或醛产生光学活性醇, 手性中心 这些过程将用于一个新的内酯环 膨胀反应,提供了一系列密切相关的手性 可以应用于硫霉素和糖部分的内酯 阿霉素
英文摘要
Adriamycin, a member of the anthracycline family of antibiotics, has been found to be highly effective against a wide variety of cancers. Thienamycin is a Beta-lactam antibiotic isolated from streptomyces cattleya that has shown unusually high potency against both gram-positive and gram-negative bacteria. The chirality in these molecules plays a crucial role in their biological activities. Hence the synthesis of the optically active forms of these compounds is important. We have recently developed two new methods for preparing optically-active molecules: asymmetric reductions via trialkylboranes, and control of stereochemistry at the migration terminus of organoborate rearrangements. The asymmetric reduction of propargyl ketones makes essentially optically-pure propargyl alcohols readily available, and the acetylene handle makes alcohols attractive intermediates for further elaboration. The study of organoborane rearrangements has made optically-active allylboranes readily accessible for the first time. Addition of these organoboranes to a ketone or aldehyde produces optically-active alcohols with several contiguous chiral centers. These processes will be used in a novel lactone ring expansion reaction that provides a series of closely related chiral lactones that can be applied to both thienamycin and the sugar portion of adriamycin.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ASYMMETRIC REDUCTIONS VIA TRIALKYLBORANES
ASYMMETRIC REDUCTIONS VIA TRIALKYLBORANES
ASYMMETRIC REDUCTIONS VIA TRIALKYLBORANES
海外基金